Dantrolene is neuroprotective in vitro, but does not affect survival in SOD1G93A mice

Neuroscience

Volumn 220, Issue , 2012, Pages 26-31

  Staats, K A ^a,b   Van Rillaer, M ^a   Scheveneels, W ^a,b   Verbesselt, R ^a   Van Damme, P ^a,b,c   Robberecht, W ^a,b,c   Van Den Bosch, L ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c Department of Neurology ^*  (Belgium)

Author keywords

Amyotrophic lateral sclerosis; Endoplasmic reticulum; Motor neuron disease; Neurodegeneration; Ryanodine receptors

Indexed keywords

ALANINE; CALCIUM; DANTROLENE; GLYCINE; RYANODINE RECEPTOR; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CELL COUNT; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOPLASMIC RETICULUM; GENE EXPRESSION; IMMUNOREACTIVITY; IN VITRO STUDY; MOTONEURON; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CALCIUM; DANTROLENE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SUPEROXIDE DISMUTASE;

EID: 84864403738     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.06.050     Document Type: Article

References (23)

1. Aslan A., Cemek M., Buyukokuroglu M.E., Altunbas K., Bas O., Yurumez Y., Cosar M. Dantrolene can reduce secondary damage after spinal cord injury. Eur Spine J 2009, 18:1442-1451.
2. Chen X., Tang T.S., Tu H., Nelson O., Pook M., Hammer R., Nukina N., Bezprozvanny I. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J Neurosci 2008, 28:12713-12724.
3. Cox L.E., Ferraiuolo L., Goodall E.F., Heath P.R., Higginbottom A., Mortiboys H., Hollinger H.C., Hartley J.A., Brockington A., Burness C.E., Morrison K.E., Wharton S.B., Grierson A.J., Ince P.G., Kirby J., Shaw P.J. Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). PLoS One 2010, 5:e9872.
4. Frandsen A., Schousboe A. Mobilization of dantrolene-sensitive intracellular calcium pools is involved in the cytotoxicity induced by quisqualate and N-methyl-D-aspartate but not by 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionate and kainate in cultured cerebral cortical neurons. Proc Natl Acad Sci U S A 1992, 89:2590-2594.
5. Grosskreutz J., Van Den Bosch L., Keller B.U. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium 2010, 47:165-174.
6. Hernandez-Fonseca K., Massieu L. Disruption of endoplasmic reticulum calcium stores is involved in neuronal death induced by glycolysis inhibition in cultured hippocampal neurons. J Neurosci Res 2005, 82:196-205.
7. Inan S., Wei H. The cytoprotective effects of dantrolene: a ryanodine receptor antagonist. Anesth Analg 2010, 111:1400-1410.
8. Jahn K., Grosskreutz J., Haastert K., Ziegler E., Schlesinger F., Grothe C., Dengler R., Bufler J. Temporospatial coupling of networked synaptic activation of AMPA-type glutamate receptor channels and calcium transients in cultured motoneurons. Neuroscience 2006, 142:1019-1029.
9. Julien J.P., Kriz J. Transgenic mouse models of amyotrophic lateral sclerosis. Biochim Biophys Acta 2006, 1762:1013-1024.
10. Kihira T., Utunomiya H., Kondo T. Expression of FKBP12 and ryanodine receptors (RyRs) in the spinal cord of MND patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2005, 6:94-99.
11. Kimlicka L., Van Petegem F. The structural biology of ryanodine receptors. Sci China Life Sci 2011, 54:712-724.
12. Liu J., Tang T.S., Tu H., Nelson O., Herndon E., Huynh D.P., Pulst S.M., Bezprozvanny I. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci 2009, 29:9148-9162.
13. Logroscino G., Traynor B.J., Hardiman O., Chio A., Mitchell D., Swingler R.J., Millul A., Benn E., Beghi E. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010, 81:385-390.
14. MacLennan D.H., Duff C., Zorzato F., Fujii J., Phillips M., Korneluk R.G., Frodis W., Britt B.A., Worton R.G. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990, 343:559-561.
15. Miller R.G., Mitchell J.D., Lyon M., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007, CD001447.
16. Rothstein J.D., Kuncl R.W. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995, 65:643-651.
17. Teuling E., van Dis V., Wulf P.S., Haasdijk E.D., Akhmanova A., Hoogenraad C.C., Jaarsma D. A novel mouse model with impaired dynein/dynactin function develops amyotrophic lateral sclerosis (ALS)-like features in motor neurons and improves lifespan in SOD1-ALS mice. Hum Mol Genet 2008, 17:2849-2862.
18. 2+-dependent AMPA receptor-mediated motoneuron death. J Neurosci 2003, 23:4942-4950.
19. Van Den Bosch L., Robberecht W. Different receptors mediate motor neuron death induced by short and long exposures to excitotoxicity. Brain Res Bull 2000, 53:383-388.
20. Van Den Bosch L., Van Damme P., Bogaert E., Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 2006, 1762:1068-1082.
21. 2+-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci 2000, 180:29-34.
22. van Es M.A., Van Vught P.W., Blauw H.M., Franke L., Saris C.G., Andersen P.M., Van Den Bosch L., de Jong S.W., van 't Slot R., Birve A., Lemmens R., de Jong V., Baas F., Schelhaas H.J., Sleegers K., Van Broeckhoven C., Wokke J.H., Wijmenga C., Robberecht S.W., Veldink W., Ophoff R.A., van den Berg L.H. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol 2007, 6:869-877.
23. Wei H., Perry D.C. Dantrolene is cytoprotective in two models of neuronal cell death. J Neurochem 1996, 67:2390-2398.